Thus, several PDE inhibitors are considered as possible drugs for COVID-19 treatment.233 The phase III clinical trials of PDE4 selective-inhibitor apremilast and ensifentrine (NCT04590586, NCT02735707) for COVID-19 treatment are ongoing. This evidence concerns the gene PDE4A and COVID-19.